Avastin gains accelerated approval for breast cancer
Executive Summary
Genetech's Avastin (bevacizumab) gains accelerated approval Feb. 22 for first-line treatment of metastatic HER-2 negative breast cancer, in combination with paclitaxel. Based on progression-free survival, the approval follows a mixed vote from the Oncologic Drugs Advisory Committee (1"The Pink Sheet," Dec. 17, 2007, p. 15). Visit 2www.ThePinkSheetDAILY.com for coverage of the late-breaking approval. To sign up for a free trial, visit our website or call 800-332-2181...